10-Q · May 18, 2026
OS Therapies reported significant operating losses for the first quarter of 2026, with a net loss of approximately $10.4 million compared to $3.9 million in the prior year, reflecting increased research and development…
Earnings analysis · 10-Q
OSTX earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The 10-Q does not provide current-quarter revenue, margins, EPS, segment revenue or cash-flow figures, so operating trends cannot be assessed from the supplied filing text. Liquidity remains highly constrained, with…
Read full summary
The 10-Q does not provide current-quarter revenue, margins, EPS, segment revenue or cash-flow figures, so operating trends cannot be assessed from the supplied filing text. Liquidity remains highly constrained, with approximately $205,000 of cash and an accumulated deficit of approximately $86.2 million as of June 30, 2026; management stated that these conditions raise substantial doubt about going-concern status. The subsequent $5,405,405.42 secured-note financing provides near-term capital but introduces nine-month maturities, restrictive covenants, default risks and significant potential dilution. Disclosure controls were also deemed ineffective as of June 30, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Financing Provides Near-Term Capital
The company issued Secured Notes with aggregate principal of $5,405,405.42 on August 10, 2026, with up to an additional $5,000,000 available under the Second Tranche. Proceeds are intended to support clinical development, regulatory activities and working capital.
-
Capital Raised Despite Limited Cash
Management reported approximately $205,000 of cash as of June 30, 2026, while the company had an accumulated deficit of approximately $86.2 million. The filing states that the financing is intended to support ongoing operations and clinical programs.
-
Vendor Services Settled With Equity
During the three months ended June 30, 2026, the company issued 30,000 common shares to vendors in exchange for services, preserving cash for operating needs.
-
Defined Insider Trading Plan
The company disclosed that its CEO adopted a Rule 10b5-1 plan providing for sales of up to 600,000 common shares, with sales scheduled to begin September 23, 2026.
What to watch
-
Going-Concern and Liquidity Risk
As of June 30, 2026, the company had approximately $205,000 of cash, an accumulated deficit of approximately $86.2 million and recurring losses and negative operating cash flows since inception. Management stated these conditions raise substantial doubt about the company’s ability to continue as a going concern.
-
Short-Dated Secured Debt Risk
The August financing adds Secured Notes totaling $5,405,405.42, with the notes maturing nine months from the applicable advance date. A default could permit acceleration and foreclosure on substantially all assets securing the notes.
-
Substantial Potential Dilution
The filing identifies potential dilution and selling pressure from 1,401,786 shares issuable upon conversion of Series A preferred stock, warrants for up to 15,234,585 shares, pre-funded warrants for up to 3,324,108 shares and options for up to 8,422,500 shares. Separately, the CEO’s plan permits sales of up to 600,000 shares beginning September 23, 2026.
-
Costly Default Provisions
The Secured Notes include events of default under which obligations may increase to 125% of the outstanding amount, default interest may accrue at up to 24% per annum and a $10,000 monthly monitoring fee may apply until the default is cured or waived.
-
Ineffective Disclosure Controls
Management concluded as of June 30, 2026 that disclosure controls and procedures were not effective due to inadequate segregation of duties, insufficient written policies and procedures, and an insufficient number of personnel with appropriate U.S. GAAP knowledge and experience.
Management's outlook
No quantitative revenue or EPS guidance was provided in the 10-Q; outlook was not disclosed.
Earlier filings 4
10-K · March 31, 2026
OS Therapies’ 2025 Form 10-K highlights a clinically meaningful Phase IIb outcome for OST-HER2 (33% event-free at 12 months vs 20% historical control; 75% two-year overall survival (27 of 36) vs 40% published control, p…
10-Q · November 14, 2025
OS Therapies reported a sharply wider quarterly operating loss of $(6,879,595) and net loss of $(6,879,530) for the three months ended September 30, 2025, driving diluted loss per share to $(0.21). Cash fell to…
10-Q · May 15, 2025
OS Therapies reported no revenue and a widening loss in Q1 2025: net loss was $3,876,859 and loss from operations was $4,999,486, driven by a sharp increase in R&D and G&A spend. Cash fell to $2,971,007 at March 31,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.